Last reviewed · How we verify
relapsed or refractory (r/r) large B-cell lymphoma
Approved treatments
- Kymriah · Novartis Pharmaceuticals Corporation
Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein. - Kymriah · Novartis Pharmaceuticals Corporation
Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- relapsed or refractory (r/r) large B-cell lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- relapsed or refractory (r/r) large B-cell lymphoma treatment landscape brief
- relapsed or refractory (r/r) large B-cell lymphoma treatment updates RSS
Frequently asked questions about relapsed or refractory (r/r) large B-cell lymphoma
What drugs treat relapsed or refractory (r/r) large B-cell lymphoma?
Tracked treatments include Kymriah.
What is the treatment for relapsed or refractory (r/r) large B-cell lymphoma?
Standard treatment for relapsed or refractory (r/r) large B-cell lymphoma includes Kymriah. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: relapsed or refractory (r/r) large B-cell lymphoma patent cliff · relapsed or refractory (r/r) large B-cell lymphoma CI report
- Treatment: Kymriah · Novartis Pharmaceuticals Corporation
- Treatment: Kymriah · Novartis Pharmaceuticals Corporation
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing